Recurrence risk after withdrawal of antiepileptic drugs in children with epilepsy: a prospective study

J Ramos-Lizana1, J Aguirre-Rodríguez, P Aguilera-López

  • 1Pediatric Neurology Unit, Department of Pediatrics, Torrecárdenas Hospital, Almería, Spain. jramoslizana@telefonica.net

Insights

The risk of epilepsy recurrence after stopping antiepileptic drugs in children is low, with most children remaining seizure-free. Etiology and epilepsy syndrome are key factors predicting recurrence risk.

Area of Science:

  • Pediatric Neurology
  • Epileptology

Background:

  • Epilepsy is a common neurological disorder in children.
  • Withdrawal of antiepileptic drugs (AEDs) is a crucial step in managing childhood epilepsy.
  • Predicting recurrence risk after AED withdrawal is essential for clinical decision-making.

Purpose of the Study:

  • To determine the recurrence risk of seizures after antiepileptic drug withdrawal in children with epilepsy.
  • To identify factors associated with increased seizure recurrence after AED discontinuation.

Main Methods:

  • Prospective follow-up of children under 14 with two or more unprovoked seizures.
  • Inclusion criteria: seen between 1994-2004, no prior evaluation at other centers.
  • Medication withdrawal proposed after a remission period; recurrence risk assessed using Kaplan-Meier estimates and Cox proportional hazards model.

Main Results:

  • Of 353 children, 238 achieved remission and were proposed AED withdrawal; 216 accepted.
  • The estimated seizure recurrence risk was 23% at 2 years and 28% at 5 years post-withdrawal.
  • Remote symptomatic etiology, varied seizure types, and history of febrile or neonatal seizures significantly increased recurrence risk.

Conclusions:

  • Recurrence risk after antiepileptic drug withdrawal in children is generally low.
  • Epilepsy etiology and syndromic diagnosis are the primary predictors of seizure recurrence.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types: